Cowen Downgrades Alimera Sciences (ALIM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Alimera Sciences (ALIM) Misses Q1 EPS by 4c
May 4, 2016 5:15 PM EDTAlimera Sciences (NASDAQ: ALIM) reported Q1 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.83 million.
"In the U.S. we were pleased to see a record month for... More
